SARS-CoV-2 - Colchicine - Therapeutic Candidates

SARS-CoV-2 - Colchicine - Therapeutic Candidates


Colchicine is an anti-inflammatory drug used in rheumatology and particularly for the treatment of gouty arthritis or gout. Colchicine is also used in the treatment of other pathologies such as chronic atrophic polychondritis or acute pericarditis after failure of aspirin. 
Studies have shown that SARS-CoVs activate NLRP3 inflammasomes, intracytoplasmic particles that stimulate the release of pro-inflammatory cytokines. In particular, colchicine is believed to inhibit the assembly of the NLRP3 inflammasome and thus the release of cytokines, in particular interleukin-1 beta and interleukin-6. Colchicine is believed to inhibit certain functions of the inflammasome, a component of the immune system that plays a role in triggering cytokine shock and the associated inflammatory cascade. Targeting the inflammatory response with colchicine may therefore reduce complications related to Covid-19 in adults at risk or with signs of inflammatory storm. Three studies are currently underway to investigate the effects of colchicine on Covid-19, the largest, called COLCORONA, involves 6000 patients in Canada.

Cat#
Description
Size
Price Excl. VAT
M3460-500mg
 500 mg 
271252-100mg
 100mg 
271252-25mg
 25mg 
271252-50mg
 50mg 
414878-10mg
 10mg 
414878-25mg
 25mg 
10-2310-2g
 2 g 
10-2310-500mg
 500 mg 
L474300-100mg
 100mg 
008006-10mg
 10mg 
008007-5mg
 5mg 
469803-2,5mg
 2.5mg 
L474310-2.5mg
 2.5mg 
469803-25mg
 25mg 
007022-10mg
 10mg 
007024-2,5mg
 2.5mg 
A3324-250mg
 250mg 
A3324-500mg
 500mg 
abx082250-100mg
 100mg 
Number of results per page : 10 50 250